Jubilant Pharmova gets 6 observations from USFDA for its facility at Roorkee
News

Jubilant Pharmova gets 6 observations from USFDA for its facility at Roorkee

he US FDA has issued six observations pursuant to the completion of the audit.

  • By IPP Bureau | August 03, 2022

Jubilant Pharmova Limited announced that the United States Food and Drug Administration (USFDA) has recently concluded audit of the Solid Dosage Formulations facility at Roorkee, India of Jubilant Generics, a subsidiary of its wholly owned subsidiary Jubilant Pharma Limited.

The US FDA has issued six observations pursuant to the completion of the audit. The company will submit an action plan on the observations and will engage with US FDA for next steps.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International